Urothelial Carcinoma: Advances in Immuno-Oncology

Host: Jay D. Raman, MD, FACS
Co-Hosts: Andrea Apolo, MD and Sima Porten, MD

CME Available: auau.auanet.org/node/37325

At the conclusion of this activity, participants will be able to
1. Determine the pros/cons of sequencing strategies with chemotherapy and immunotherapy in first line metastatic urothelial carcinoma.
2. Prioritize treatment options in first line metastatic urothelial carcinoma.
3. Evaluate second line options for metastatic urothelial carcinoma.

ACKNOWLEDGEMENTS:
This series is supported by independent educational grants from:
Astellas
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme

Ver todos los episodios